All articles by Salong Debbarma

Salong Debbarma

Glaukos completes patient enrolment in Phase II trial of GLK-321

Glaukos has completed patient enrolment in its Phase II clinical trial evaluating GLK-321 for the treatment of Demodex blepharitis, using…
First patient dosed in Racura’s HARNESS-1 trial of RC220

Racura Oncology has dosed the first patient in the Phase Ia/b HARNESS-1 trial assessing RC220 in combination with osimertinib for…
Ollin Biosciences secures $330m to fund Phase III OLN324 trials

Ollin Biosciences has completed a $330m Series B financing round to support the global Phase III development of its lead…
Viking Therapeutics commences Phase I trial of VK3019

Viking Therapeutics has commenced a Phase I clinical trial of VK3019, a dual amylin and calcitonin receptor agonist, which is…
Ascletis receives FDA clearance for Phase I trial of obesity treatment

Ascletis Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to initiate a Phase…

Pfizer reports topline data from SigVie-002 study for NSCLC

Pfizer has reported topline data from the Phase III SigVie-002 study investigating sigvotatug vedotin in adults with previously treated, locally…
GondolaBio reports positive data from Phase IIa trial of PORT-77

GondolaBio has reported positive results from its Phase IIa GATEWAY study of PORT-77, an investigational oral ABCG2 inhibitor, which aims…
Medidata establishes Academic Site Advisory Board for clinical trials

Dassault Systèmes brand Medidata has announced the formation of its Academic Site Advisory Board to address the distinct operational and…
Kither Biotech concludes Phase I study of KIT2014

Kither Biotech has completed its Phase I clinical trial assessing KIT2014, an inhaled peptide therapy designed for the treatment of…
First participant receives Evategrel in CureGene’s trial

CureGene Pharmaceutical has dosed the first participant in its pivotal clinical trial of Evategrel (CG-0255), a next-generation antiplatelet therapy, in…